How Hyperinflation Affects the P&MA Strategy of Innovative Drugs

Published on January 19, 2023

Inflation rates keep increasing in Argentina, making it all the more difficult for manufacturers to design good Pricing and Market Access (P&MA) of innovative medicines. In this article, experts Paloma Gutierrez, Pedro Santana, and Vicente Lumbreras explain what manufacturers can do to navigate this difficult landscape.

Argentina has been battling inflation for years, with annual rates among the highest in the world. Despite government measures, the 2021 inflation rate is above 50 percent and there are no signs of significant deceleration for 2022.

Surpassing this already staggering rise in inflation, pharmaceutical drug prices increased 65.9 percent in 2021. As a result, out-of-pocket costs of common prescription drugs have spiked, causing serious patient affordability issues. Several consumer associations have pushed for a government freeze on drug prices, similar to the ones put in place for other first-necessity goods, but it is uncertain…